bladder cancer

Work-related bladder cancer risk on the riseWork-related risks for bladder cancer are on the rise, but the occupations putting workers at risk seem to be evolving, according to a meta-analysis published online in JAMA Oncology (Oct. 8, 2015).
The promise of PD-1 ligand pathway in treating bladder cancerResearchers have recently made progress in understanding a fundamental signaling cascade, the Programmed Death 1 (PD-1) receptor-ligand pathway,1 which holds long-awaited promise in bladder cancer intervention.
Reprogramming cancer with a codeResearchers at Mayo Clinic’s Jacksonville, Fla., campus reported a discovery that could be the code for reprogramming cancer cells back to normal.
Product Preview: Agreement reached for phase III clinical trial of bladder Ca agentIn this installment of "Product Preview," also look for information on products in the pipeline for renal cell carcinoma and interstitial cystitis.
Study: No significant link between diabetes Tx, bladder Ca
Study: No significant link between diabetes Tx, bladder CaA new study reports no statistically significant increase in the risk of bladder cancer among patients treated with the diabetes drug pioglitazone (Actos), despite previous studies suggesting an association.
Best of AUA 2015: PCa surveillance, surgical controversies create buzzUrology Times’ “Best of AUA 2015” report provides a guide to the meeting’s take-home messages in 15 therapeutic areas—an information-packed, condensed summary of the top papers and presentations.
FDA drug approvals-March 2015FDA actions in brief, breakthrough designation, recommended for approval, priority review, fast-track designations
Best of GU Cancers 2015: Dr. Thrasher’s picks and moreNew, large-scale studies on active surveillance, IMRT complications, and robotic versus open prostatectomy were among the highlights of this year’s Genitourinary Cancers Symposium.
January 2015 Product Preview: FDA committee recommends approval of complicated UTI agentDrugs and devices in the pipeline from Actavis, Genomic Health, Lipella Pharmaceuticals, Polaris Group, Innocrin Pharmaceuticals, OncoGenex Pharmaceuticals, Heat Biologics, Repros Therapeutics, and Sophiris Bio.
Immunotherapy will define new era of GU cancer care
Immunotherapy will define new era of GU cancer careIn this interview, Arie Belldegrun, MD, discusses the benefits of cancer immunotherapy, the importance of a multidisciplinary treatment approach, and what the future holds for this treatment.